Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 472 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| P ParcelBioCompany profile Develops potent and durable mRNA medicines using the APEXm platform for autoimmune and oncology Develops potent and durable mRNA medicines using the APEXm platform for autoimmune and oncology | $13M | Seed | Biotech | United States | Investors | |
| M Develops cultivated meat production technology | £10.4M | Series A | Biotech, Foodtech | United Kingdom | Investors | |
| C CellCentricCompany profile Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma | $220M | Series DSeries C+ | Biotech | United Kingdom | Investors | |
| KB Kanvas BiosciencesCompany profile Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy | $48M | Series A | Biotech | United States | Investors | |
| LT LTZ TherapeuticsCompany profile LTZ Therapeutics develops cancer immunotherapies that target myeloid biology. LTZ Therapeutics develops cancer immunotherapies that target myeloid biology. | $38M | Undisclosed | Biotech | United States | Investors | |
| SB Signadori BioCompany profile Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage | €11.1M | Seed+Seed | Biotech | France | Investors | |
| PH Pacific HybreedCompany profile Develops high-performance hybrid oyster and clam seed to improve yield and resilience for shellfish farmers Develops high-performance hybrid oyster and clam seed to improve yield and resilience for shellfish farmers | $1M | Seed | Biotech, Agritech | United States | Investors | |
| 4P 4D PathCompany profile Digital biomarkers designed to predict cancer treatment response from routine biopsy images. Digital biomarkers designed to predict cancer treatment response from routine biopsy images. | Undisclosed | StrategicUndisclosed | Biotech, Healthtech | United States | Investors Undisclosed | |
| N NavidenceCompany profile Provides AI-native platform with standardized computable definitions of diseases and outcomes for real-world evidence research Provides AI-native platform with standardized computable definitions of diseases and outcomes for real-world evidence research | Undisclosed | StrategicUndisclosed | Biotech, Healthtech | United States | Investors | |
| LB Latus Bio, Inc.Company profile Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2 Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2 | $97M | Series A | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.